Alisertib

Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib monotherapy for HER2-mutated tumors, based on Phase II SUMMIT trial results.

Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib monotherapy for HER2-mutated tumors, based on Phase II SUMMIT trial results. This addition aims to improve treatment options for recurrent or metastatic disease.

Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib for HER2-mutated tumors. This addition is based on the Phase II SUMMIT trial results, offering neratinib as a second-line therapy option for patients with HER2-mutated recurrent or metastatic cervical cancer.

Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib monotherapy for HER2-mutated tumors, based on Phase II SUMMIT trial results.

Tempus announces four abstracts accepted for presentation at the 2024 San Antonio Breast Cancer Symposium, highlighting research on molecular profiling, tumor immune microenvironment, and biomarkers for CDK4/6 inhibitor resistance.

Developed a system using the air–liquid interface method to maintain lymphoma tissues ex vivo, preserving viability, proliferation, structure, and cellular composition. Optimized conditions using RGD-hydrogel and BAFF, maintaining B-cell viability and tissue architecture for up to 1 week. Human lymphomoids retained cell heterogeneity and could be used to test sensitivity to different compounds, with results largely matching clinical responses.

The biotech industry is growing rapidly due to advancements in genomic research, personalized medicine, and innovative platforms, with key stocks like HRMY, TRDA, and PBYI leading the charge. The global biotechnology market is projected to reach $4.61 trillion by 2034, driven by increased investment, favorable regulations, and high demand for novel therapies. TRDA specializes in EEV therapeutics for neuromuscular diseases, HRMY focuses on rare and neurological diseases, and PBYI develops cancer treatments, all showing strong financials and growth potential.

Puma Biotechnology granted a 7,500-share restricted stock unit award to a new non-executive employee on Dec 2, 2024, under its 2017 Employment Inducement Incentive Award Plan. The award vests over three years, with vesting conditions tied to continued employment.

Puma Biotechnology (NASDAQ: PBYI) approved a 7,500-share restricted stock unit award for a new non-executive employee under its 2017 Employment Inducement Incentive Award Plan. The award vests over three years, with one-third vesting on December 1, 2025, and one-sixth every six months thereafter, contingent on continued employment, complying with Nasdaq Listing Rule 5635(c)(4).